SMT201500158B - Pellet farmaceutico di fattore di crescita epidermico somministrabile oralmente - Google Patents

Pellet farmaceutico di fattore di crescita epidermico somministrabile oralmente

Info

Publication number
SMT201500158B
SMT201500158B SM201500158T SM201500158T SMT201500158B SM T201500158 B SMT201500158 B SM T201500158B SM 201500158 T SM201500158 T SM 201500158T SM 201500158 T SM201500158 T SM 201500158T SM T201500158 B SMT201500158 B SM T201500158B
Authority
SM
San Marino
Prior art keywords
growth factor
epidermal growth
pharmaceutical pellet
oral epidermal
factor pharmaceutical
Prior art date
Application number
SM201500158T
Other languages
English (en)
Italian (it)
Inventor
Gomez Raimundo Ubieta
Barreto Ana Aguilera
Diaz Eduardo Martinez
Meireles Rolando Paez
Guerra Antonio Sereno
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of SMT201500158B publication Critical patent/SMT201500158B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201500158T 2010-02-12 2015-07-03 Pellet farmaceutico di fattore di crescita epidermico somministrabile oralmente SMT201500158B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382033A EP2364690A1 (en) 2010-02-12 2010-02-12 Orally administrable pharmaceutical pellet of epidermal growth factor
EP11702645.0A EP2533758B1 (en) 2010-02-12 2011-02-10 Orally administrable pharmaceutical pellet of epidermal growth factor
PCT/EP2011/051918 WO2011098499A1 (en) 2010-02-12 2011-02-10 Orally administrable pharmaceutical pellet of epidermal growth factor

Publications (1)

Publication Number Publication Date
SMT201500158B true SMT201500158B (it) 2015-09-07

Family

ID=42355395

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500158T SMT201500158B (it) 2010-02-12 2015-07-03 Pellet farmaceutico di fattore di crescita epidermico somministrabile oralmente

Country Status (21)

Country Link
US (1) US9205130B2 (xx)
EP (2) EP2364690A1 (xx)
JP (1) JP5778184B2 (xx)
KR (1) KR101745750B1 (xx)
CN (1) CN102753146B (xx)
AR (1) AR080144A1 (xx)
AU (1) AU2011214421B8 (xx)
BR (1) BR112012020223B8 (xx)
CA (1) CA2789055C (xx)
DK (1) DK2533758T3 (xx)
ES (1) ES2537704T3 (xx)
HR (1) HRP20150643T1 (xx)
HU (1) HUE024986T2 (xx)
MX (1) MX2012009217A (xx)
PL (1) PL2533758T3 (xx)
PT (1) PT2533758E (xx)
RS (1) RS54098B1 (xx)
RU (1) RU2540503C2 (xx)
SI (1) SI2533758T1 (xx)
SM (1) SMT201500158B (xx)
WO (1) WO2011098499A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102432737B (zh) * 2011-09-07 2015-02-25 张绍国 一种缓释肠溶丙烯酸树脂乳胶液及其制法
EP3482771B1 (en) * 2013-03-14 2023-01-18 Société des Produits Nestlé S.A. Manufacture of peanut formulations for oral desensitization
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62149622A (ja) 1985-12-24 1987-07-03 Wakunaga Pharmaceut Co Ltd 腸機能改善剤
US4743679A (en) * 1986-02-24 1988-05-10 Creative Biomolecules, Inc. Process for producing human epidermal growth factor and analogs thereof
DE3778275D1 (de) * 1986-08-07 1992-05-21 Roehm Gmbh Verfahren zur herstellung eines redispergierbaren kunststoffpulvers.
JPH01246223A (ja) 1988-03-28 1989-10-02 Hitachi Chem Co Ltd 潰瘍治療剤
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
WO1999030671A2 (en) * 1997-12-15 1999-06-24 Ron Eyal S Aspected particles for oral delivery
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US20040126358A1 (en) 2002-09-16 2004-07-01 Warne Nicholas W. Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
DE10332160A1 (de) * 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2005058345A1 (en) 2003-12-16 2005-06-30 University Technologies International Inc. A treatment for necrotizing enterocolitis
WO2007095288A2 (en) * 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
MXPA06013015A (es) * 2006-11-09 2007-02-07 Gastronomia Molecular S A Nuevo proceso de elaboracion y estabilidad de un producto nutritivo de amaranto.
CA2734275A1 (en) * 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins

Also Published As

Publication number Publication date
DK2533758T3 (da) 2015-06-22
EP2364690A1 (en) 2011-09-14
WO2011098499A1 (en) 2011-08-18
AR080144A1 (es) 2012-03-14
PT2533758E (pt) 2015-08-26
KR20120114402A (ko) 2012-10-16
AU2011214421B8 (en) 2014-01-30
SI2533758T1 (sl) 2015-08-31
EP2533758A1 (en) 2012-12-19
US9205130B2 (en) 2015-12-08
BR112012020223B8 (pt) 2021-05-25
PL2533758T3 (pl) 2015-10-30
CA2789055A1 (en) 2011-08-18
KR101745750B1 (ko) 2017-06-09
ES2537704T3 (es) 2015-06-11
JP2013519649A (ja) 2013-05-30
BR112012020223A2 (pt) 2017-07-04
RS54098B1 (en) 2015-10-30
AU2011214421A1 (en) 2012-08-23
RU2012139030A (ru) 2014-03-20
US20120308661A1 (en) 2012-12-06
RU2540503C2 (ru) 2015-02-10
CN102753146B (zh) 2014-11-26
CA2789055C (en) 2017-07-18
AU2011214421B2 (en) 2013-12-19
HRP20150643T1 (hr) 2015-08-14
JP5778184B2 (ja) 2015-09-16
EP2533758B1 (en) 2015-04-08
CN102753146A (zh) 2012-10-24
HUE024986T2 (en) 2016-01-28
BR112012020223B1 (pt) 2021-05-11
AU2011214421A8 (en) 2014-01-30
MX2012009217A (es) 2012-11-23

Similar Documents

Publication Publication Date Title
HK1259250A1 (zh) 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的藥物製劑
SMT201700008B (it) Composizione farmaceutica
GB201010193D0 (en) Medicinal use
DK2525798T3 (da) Anæstetisk formulering
GB201008005D0 (en) Pharmaceutical compounds
FI9350U1 (fi) Ravintoformulaatioita
DK2652652T3 (da) Medikmentadministration
EE201300005A (et) Ravimkoostis
IL232305B (en) Pharmacy preparations
DK2542224T3 (da) Oral farmaceutisk sammensætning indeholdende dabigatranetexilat
GB2486567B (en) Pharmaceutical formulation
HK1180541A1 (en) Stabilized statin formulations
BR112013008074A2 (pt) combinações farmacêuticas
SMT201500158B (it) Pellet farmaceutico di fattore di crescita epidermico somministrabile oralmente
IT1401276B1 (it) Composto medicinale naturale
HK1179164A1 (zh) 包含肉豆蔻酰氨基丙基二甲基苄基氯化銨的藥物製劑
HK1200133A1 (en) Oral care gels
FI9608U1 (fi) Formulaatiot
BR112012029887A2 (pt) composição farmacêutica
FI20105327A (fi) Farmaseuttinen koostumus
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations
ES1076284Y (es) Profilactico oral femenino
IT1401468B1 (it) Contenitore per farmaci
GB201018760D0 (en) An oral dosage form